← Back to Search

Pharmacogenomic Testing for Cancer

N/A
Waitlist Available
Led By Jai Patel, PharmD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Written informed consent and HIPAA authorization for release of personal health information.
* Age ≥ 18 years at the time of consent.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, at 3 months and at 6 months after receiving the microarray profiling results
Awards & highlights

Summary

The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.

Who is the study for?
This trial is for cancer patients eligible for DPYD gene testing, which helps tailor drug dosing. Specifics about who can join are not provided, but typically participants have a certain type of cancer and meet other health standards.
What is being tested?
The study tests the 'Global Diversity Array with Enhanced PGx' microarray to see if it affects how doctors prescribe and dose cancer treatments compared to current single-gene testing methods.
What are the potential side effects?
Since this trial involves genetic testing rather than drug treatment, there are no direct side effects from the intervention itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, at 3 months and at 6 months after receiving the microarray profiling results
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, at 3 months and at 6 months after receiving the microarray profiling results for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of potentially actionable results based on pharmacogenomic (PGx) test
Secondary study objectives
Percentage of prescriptions that trigger PGx best practice advisory (BPA) alerts
Taking actions from PGx best practice advisory alerts
The presence of at least one PGx best practice advisory (BPA) alert
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pharmacogenomic TestingExperimental Treatment1 Intervention
A pharmacogenomic (PGx) microarray (multi-gene) panel will be performed to test for genetic variations in genes related to drug response.

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,263 Previous Clinical Trials
1,012,603 Total Patients Enrolled
Atrium Health Levine Cancer InstituteOTHER
23 Previous Clinical Trials
1,709 Total Patients Enrolled
Jai Patel, PharmDPrincipal InvestigatorAtrium Health Levine Cancer
1 Previous Clinical Trials
75 Total Patients Enrolled
~80 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top